ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years

May 9, 2014

House Committee Investigates ESA Safety, Urges Amgen, J&J, To Stop Promotions.

March 23, 2007

NCI Director Among Bush Appointees Asked To Submit Resignation.

December 12, 2008

Former Senator Cotton Named To NCA

April 11, 1975

BSA Strikes Down NCI Tissue Bank Plan, Calls for Audit of caBIG

March 11, 2011

NCI Staff Will Recommend That Comprehensive Recognition Be Withdrawn From Colorado Center

October 31, 1980